Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jul-Sep;43(3):194-197.
doi: 10.1097/TME.0000000000000361.

Sulfasalazine-Induced Toxic Epidermal Necrolysis: A Challenging Case During the COVID-19 Pandemic

Mohammad Shahidi-Dadras  1 , Shaghayegh Shahrigharahkoshan, Esmat Yazdi, Alireza Fatemi, Zahra Mahboubi-Fooladi, Sahar Dadkhahfar
Affiliations
Case Reports

Sulfasalazine-Induced Toxic Epidermal Necrolysis: A Challenging Case During the COVID-19 Pandemic

Mohammad Shahidi-Dadras et al. Adv Emerg Nurs J. 2021 Jul-Sep.

Abstract

COVID-19 is a major health issue, and patients with underlying conditions are more susceptible to catastrophic outcomes. Toxic epidermal necrolysis (TEN) is a severe systemic disease caused by an immune system hypersensitive reaction. We present a case of TEN induced following sulfasalazine administration that later on complicated with COVID-19, deep vein thrombosis, pulmonary emboli, and eventually death.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The authors report no conflicts of interest.

Figures

Figure 1.
Figure 1.
Cutaneous manifestation of toxic epidermal necrolysis: the tense blisters along with sheet-like epidermal detachment of the body.
Figure 2.
Figure 2.
Cutaneous manifestation of toxic epidermal necrolysis: blisters on the palms.
Figure 3.
Figure 3.
Histopathological features: blisters along with suprabasilar acantholysis of the skin.
See this image and copyright information in PMC

References

    1. Al-Samkari H., Karp Leaf R. S., Dzik W. H., Carlson J. C. T., Fogerty A. E., Waheed A., Rosovsky R. P. (2020). COVID-19 and coagulation: Bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood, 136(4), 489–500. doi:10.1182/blood.2020006520 - PMC - PubMed
    1. Bolognia J. L., Schaffer J. V., Cerroni L., Callen J. P. (Eds.). (2018). Dermatology (Vol. 1, 4th ed.). Edinburgh, England: Elsevier.
    1. Favalli E. G., Ingegnoli F., De Lucia O., Cincinelli G., Cimaz R., Caporali R. (2020). COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmunity Reviews, 19(5), 102523. doi:10.1016/j.autrev.2020.102523 - PMC - PubMed
    1. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. Retrieved November 25, 2020, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview...
    1. Frey N., Bodmer M., Bircher A., Jick S. S., Meier C. R., Spoendlin J. (2019). Stevens–Johnson syndrome and toxic epidermal necrolysis in association with commonly prescribed drugs in outpatient care other than anti-epileptic drugs and antibiotics: A population-based case–control study. Drug Safety, 42(1), 55–66. doi:10.1007/s40264-018-0711-x - PubMed

Publication types